Efficacy and tolerability of orlistat in the treatment of obesity: A 6-month dose-ranging study

European Journal of Clinical Pharmacology

Volumn 54, Issue 2, 1998, Pages 125-132

  Van Gaal, L F ^a   Broom, J I ^b   Enzi, G ^c   Toplak, H ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF GRAZ   (Austria)

Author keywords

Obesity; Orlistat

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; ENZYME INHIBITOR; PLACEBO; RETINOL; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL LIPASE; VITAMIN B GROUP; VITAMIN D;

ABDOMINAL PAIN; ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET; DIVERTICULITIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FAT INTAKE; FECES INCONTINENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LACTONES; LIPASE; MALE; MIDDLE AGED; OBESITY;

EID: 0031946729     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050433     Document Type: Article

References (33)

1. Foreyt J, Goodrick (1995) The ultimate triumph of obesity. Lancet 346: 134-135
2. Higgins M, Kannel W, Garrison R, Pinsky J, Strokes J III (1988) Hazards of obesity. The Framingham experience. Acta Med Scand 723 [Suppl]: 23-36
3. Must A, Jacques PF, Dallal GE, Bajema CJ, Dietz W (1992) Long-term morbidity and mortality of overweight adolescents. A follow-up of the Havard growth study of 1922 1935. N Engl J Med 327: 1350-1355
4. Pi-Sunyer FX (1993) Medical hazards of obesity. Ann Intern Med 119: 655-660
5. Ferraninni E (1996) Concerns of an editor for the diabetologist. Diabetologia 39: 1-2
6. Prentice AM, Jebb SA (1995) Obesity in Britain; gluttony or sloth? B M J 7002: 437-439
7. Schutz Y (1995) Macronutrients and energy balance in obesity. Metabolism [Suppl] 3: 7-11
8. Drewnowski A, Kurth C, Holden-Wiltse J, et al (1992) Food preferences in human obesity: carbohydrates versus fats. Appetite 18: 207-221
9. Rolls BJ (1995) Carbohydrates, fats and satiety. Am J Clin Nutr 61 [Suppl]: 905-967
10. Astrup A, Bueman B, Western P, Toubro S, Raben A, Christensen NJ (1994) Obesity as an adaptation to a high fat diet: evidence from a cross-sectional study. Am J Clin Nutr 59: 350-355
11. Rolls BJ, Shide DJ (1992) The influence of dietary fat on food intake and body weight. Nutr Rev 50: 283-290
12. Goldstein DJ, Parvin JH (1994) Long term weight loss: the effect of pharmacologic agents. Am J Clin Nutr 60: 647-657
13. Hauptman JB, Jeunet FS, Hartmann D (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro180647 (tetrahydrolipstatin). Am J Clin Nutr 55: 309S-313S
14. Drent ML, Veen EA van der (1993) Lipase inhibition: a novel concept in the treatment of obesity. Int J Obesity 17: 241-244
15. Drent ML, Larsson I, William-Olsson T, Quaade F, Czubayko F, von-Bergmann K, Strobel W, Sjöström L, Veen EA van der (1995) Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obesity 19: 221-226
16. Zhi J, Melia AT, Guerciolini R, Chung J, Kingberg J, Hauptman JR (1994) Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 56: 82-85
17. Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del-Bufalo A, Pasotti E (1994) The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 46: 405-410
18. Sempos CT, Cleeman JI, Carroll MD, Johnson CL, Bachorik PS, Gordon DJ, Burt VL, Briefel RR, Brown CD, Lippell K, Rifkind BM (1993) Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Educational Program adult treatment plan. JAMA 269: 3009-3014
19. Watts GF, Lewis B, Brunt JNH, Lewis ES, Coltart DJ, Smith LDR, Mann JI, Swan AV (1992) Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 339: 563-569
20. Guy-Grand B, Apfelbaum M, Crepaldi G, Gries A, Lefebvre P, Turner P (1989) International trial of long-term dexfenfluramine in obesity. Lancet 1: 1142-1145
21. Lean ME, James WP (1986) Prescription of diabetic diets in the 1980s. Lancet 1: 723-725
22. Schofield WN (1985) Predicting basal metabolic rate, new standards and review of previous work; human nutrition. Clin Nutr 39C[Suppl 1]: 5-41
23. Lean ME, Han TS, Morrison CE (1995) Waist circumference as a measure for indicating need for weight management. B M J 311: 158-161
24. Han TS, Van-Leer EM, Seidell JC, Lean ME (1995) Waist circumference action levels in the identification of cardiovascular risk factors; prevalence study in a random sample. B M J 311: 1401-1405
25. Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L (1984) Distribution of adipose tissue and risk of cardiovascular disease and death; a 12-year follow-up of participants in the population study of women in Gothenberg, Sweden, B M J 289: 1257-1261
26. Sullivan M, Karlsson J, Sjöström L (1994) Swedish obesity subjects (SOS) an interventional study of obesity. Two-year follow-up of health and psychosocial functioning (abstract). Int J Obesity 18 [Suppl 2] 14 (052)
27. Goldstein DJ (1992) Beneficial health effects of modest weight loss. Int J Obesity 6: 397-415
28. Ashwell M (1978) Commercial weight loss programs. In: Bray G (ed) Recent advances in obesity research: II Proceedings of the Second International Congress on Obesity. Newman. London, pp 266-267
29. Volkman FR, Stunkard AJ, Woolston J, Bailey RA (1981) High attribution rates in commercial weight reduction pattern programs. Arch Intern Med 141: 426-428
30. Melia AT, Koss-Twardy SG, Zhi J (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 36: 647-653
31. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol 36: 152-159
32. James WPT, Avenell A, Broom J, Whitehead J (1997) A one-year trial for assessing the value of orlistat in the management of obesity Int J Obesity 21[Suppl 3]: 524-530
33. Vandewoude MG, Van Gaal L, De Leeuw I (1987) Changes in vitamin E status during obesity treatment. Ann Nutr Metab 31: 185-190